The National Cancer Institute (NCI) established the Cancer Immune Monitoring and Analysis Centers-Cancer Immunologic Data Commons (CIMAC-CIDC) Network as part of its Cancer Moonshot initiative, to maximize the potential of immunotherapy treatment for cancer.

Immunotherapies have emerged as highly promising approaches to treatment by harnessing patients’ immune systems to attack their cancer. While immunotherapy approaches have been remarkably successful for some patients, it has been difficult to predict which patients will derive the most clinical benefit and which patients may be at risk for adverse events. New approaches to improve and advance immunotherapies are critically needed. The overall goal of the CIMAC-CIDC Network is to advance translational research efforts using biomarkers to aid in the further development of cancer immunotherapy.

Four Cancer Immune Monitoring and Analysis Centers (CIMACs) and a Cancer Immunologic Data Commons (CIDC) form the CIMAC-CIDC Immuno-Oncology Biomarkers Network. The CIMACs and CIDC work with clinical trial investigators to design and perform studies using correlating biomarker and clinical data associated with biospecimens that are collected from NCI-sponsored clinical trials involving immunotherapy. The Partnership for Accelerating Cancer Therapies (PACT) works in collaboration with the CIMAC-CIDC Network to facilitate clinical testing of biomarkers in immunotherapy clinical trials.


Within the network, each of the four CIMACs consists of a multidisciplinary group with basic, clinical, and computational research knowledge. Each CIMAC offers a wide range of molecular and cell-based analyses using state-of-the-art platforms. The application of individual expertise facilitates biomarker identification with the potential to predict response or resistance to immunotherapies.

The CIMACs are:

Dana-Farber Cancer Institute

Icahn School of Medicine at Mount Sinai

MD Anderson Cancer Center

Stanford University


Biomarker data from the CIMACs and clinical data from clinical trials are uploaded to the Cancer Immunologic Data Commons (CIDC). CIDC provides an informatics environment for integrative, multidimensional data analysis of biomarker and clinical data, as well as data visualization across different studies. Using the CIDC platform, the CIMAC-CIDC Network and trial investigators perform their correlative analyses. As data from correlative studies from clinical trials are added to CIDC, the harmonized assays and informatics pipelines of the CIMAC-CIDC Network will facilitate cross-trial analysis to identify potential predictive biomarkers.

Through collaborative efforts among these participating institutions, the CIMAC-CIDC Network has the capacity to further the integration and translation of a wide range of research findings and dramatically improve the quality of immunotherapy for cancer patients.

The CIDC is hosted at Dana-Farber Cancer Institute.

The CIMAC-CIDC Network does not provide medical treatment or enroll patients in clinical trials. If you are a patient seeking cancer care, please contact a healthcare provider to discuss treatment options.